Alexandria Real Estate Equities (ARE) recently overhauled its main lending arrangement, securing a US$5 billion unsecured revolving credit facility, with the option to add another US$1 billion and new terms related to hybrid debt.
The new Alexandria Real Estate Equities facility lands at a time when momentum has been under pressure. The share price is down 10.4% over the past week and 8.6% over 90 days, while the 1 year total shareholder return has fallen 36.4% and the 5 year total shareholder return is down 67.2%. This signals that investors are still reassessing both risk and long term prospects around the life science REIT despite the refreshed credit firepower.
Compare Alexandria Real Estate Equities with a curated group of REITs and other property businesses that pair funding flexibility with balance sheet strength in our list of solid balance sheet and fundamentals (24 results)
Fresh credit firepower now sits against a stock that has already seen heavy value erased. Is more of Alexandria Real Estate Equities' potential still ahead of investors, or has most of the recovery already happened in the price you see today?
Most Popular Narrative: 5% Undervalued
On the most followed view, Alexandria Real Estate Equities carries a fair value estimate of $53 against a last close of $50.48, which leaves a modest gap that hinges on how its specialist lab properties perform through a tougher leasing backdrop and funding cycle.
The continued growth of global healthcare investment and R&D, with a persistent focus on addressing currently untreatable diseases, is fueling demand for specialized lab and life science space. This supports robust long-term revenue growth through high-value, resilient tenant relationships. Demographic tailwinds, especially the aging population in developed economies, are expected to drive sustained increases in healthcare innovation and spending, translating to long-duration tenancy and stable, predictable cash flows for Alexandria.
See why 88 investors see Alexandria Real Estate Equities as 5% undervalued.
Result: Fair Value of $53 (UNDERVALUED)
Still, the narrative around Alexandria Real Estate Equities could be upset if sluggish leasing and pressure on same property NOI deepen, or biotech funding stays weak for longer.
Find out about the key risks to this Alexandria Real Estate Equities narrative.
Next Steps
If the mixed sentiment around Alexandria Real Estate Equities leaves you torn, move quickly from headline impressions to the underlying numbers and weigh both sides. To see that full picture in one place, review the 3 key rewards and 3 important warning signs
Looking for more investment ideas beyond Alexandria Real Estate Equities?
If Alexandria Real Estate Equities has your attention, do not stop at a single ticker. Use the Simply Wall St screener to surface fresh ideas tailored to your style.
- Target resilience first and filter for companies with steadier risk profiles through the 30 resilient stocks with low risk scores.
- Hunt for quality at a reasonable price by checking companies that screen as attractively priced in the 30 high quality undervalued stocks.
- Spot potential future standouts early by scanning financially sound smaller players in the 16 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com